Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2014

Figures & data

Figure 1. Disposition chart showing breakdown of trial assessment at 12 months.

*Trials completing within the 12 months prior to 31 July 2016 were not required to have reported by 31 July 2016 (the study end date).

Table 1. Number of completed company-sponsored clinical trials relating to 32 new medicines approved in 2014 which had disclosed results, grouped by phase of study.

Phase	Total trials	Unevaluable at 12 months^a	Results disclosed within 12 months^b		Unevaluable at 31 July 2016^a	Results disclosed by 31 July 2016
I/II	358	35	297/323	92%	35	308/323	95%
III	237	32	194/205	95%	32	196/205	96%
IV	12	7	5/5	100%	7	5/5	100%
other	15	6	9/9	100%	6	9/9	100%
Total	622	80	505/542	93%	80	518/542	96%

^a Unevaluable if a key date was missing or unclear, or 12 months had not elapsed since trial completion.

^b Twelve months measured from the later of either the date of first regulatory approval (Europe or US) or trial completion date.

Figure 2. Percentage of trials with results disclosed.